Several gene signatures known to be favorable for T-cell-mediated tumor rejection (Fig. 3f) were also found to be deregulated in CD3+ TILs from tumor-bearing Nr2f6-deficient mice additionally treated with anti-PD-L1. The gene discussed is CD274; the disease is neoplasm.